Table 3.
Cox proportional‐hazard models for a ventricular arrhythmia outcome according to randomized treatment assignment in two key patient subgroups
| Outcome | Sacubitril/valsartan | Enalapril | Hazard ratio (95% CI) | Interaction p‐value | |||
|---|---|---|---|---|---|---|---|
| n/N (%) | Event rate per 100 patient years (95% CI) | n/N (%) | Event rate per 100 patient years (95% CI) | Unadjusted analysis a | Adjusted analysis b , c | ||
| Ischaemic aetiology | 0.020 | ||||||
| Yes | 103/2506 (4.1) | 1.9 (1.6–2.3) | 113/2530 (4.5) | 2.1 (1.7–2.5) | 0.93 (0.71–1.21) | 0.92 (0.70–1.20) | |
| No | 42/1681 (2.5) | 1.1 (0.8–1.5) | 75/1682 (4.5) | 2.1 (1.7–2.6) | 0.53 (0.37–0.78) | 0.57 (0.39–0.83) | |
| ICD/CRT‐D at baseline | 0.952 | ||||||
| Yes | 72/623 (11.6) | 5.4 (4.3–6.8) | 93/620 (15.0) | 7.0 (5.7–8.6) | 0.77 (0.57–1.05) | 0.81 (0.59–1.11) | |
| No | 73/3564 (2.0) | 0.9 (0.7–1.2) | 95/3592 (2.6) | 1.2 (1.0–1.5) | 0.76 (0.56–1.04) | 0.76 (0.56–1.04) | |
CI, confidence interval; CRT, cardiac resynchronization therapy; CRT‐D, CRT, cardiac resynchronization therapy‐defibrillator; ICD, implantable cardioverter defibrillator.
Unadjusted analysis included randomized treatment and region.
Adjusted analysis for ischaemic aetiology included randomized treatment, region, beta‐blocker use, angiotensin‐converting enzyme inhibitor use, mineralocorticoid receptor antagonist use, ejection fraction, presence of ICD or CRT, New York Heart Association class, hypertension, diabetes, past hospitalization for heart failure, log‐transformed N‐terminal pro B‐type natriuretic peptide.
Adjusted analysis for ICD/CRT‐D at baseline included randomized treatment, region, beta‐blocker use, angiotensin‐converting enzyme inhibitor use, mineralocorticoid receptor antagonist use, ejection fraction, ischaemic aetiology, New York Heart Association class, hypertension, diabetes, past hospitalization for heart failure, log‐transformed N‐terminal pro B‐type natriuretic peptide.